Issue 107 • June 2021

Are we ready for an oral vaccine?

Making trials more patient-focused

Orphan drugs face challenges in India

Relinking the pharma supply chain

Covid-19 threw a wrench into the works of global pharma manufacturing, fuelling calls to rewrite the system for a post-pandemic world

02/24/2024 02:03:10

06/01/2021 00:00:00

Go to article: Home | Relinking the pharma supply chain Go to article: In this issue Go to article: Contents Go to article: Mimotopes Company Insight Go to article: Mimotopes Go to article: Datwyler Company Insight Go to article: Datwyler Go to article: Briefing Go to article: Industry news Go to article: The pharma industry briefing Go to article: Covid-19 executive briefing by GlobalData Go to article: ILC Dover Go to article: Butterworth Go to article: Comment Go to article: New Chinese Breakthrough Therapy designation attracts foreign companies Go to article: Endometrial cancer patients expected to benefit from novel advancements Go to article: Regulatory and strategic complications of marketing an oncology drug in Asia Go to article: The biopharma revolution: navigating complexity Go to article: TRiBECA Knowledge Go to article: PerkinElmer Go to article: In Depth Go to article: What’s in a drug name?Go to article: Improving care for rare diseases in India Go to article: Focus on the patient, not the pill Go to article: Academic-industry collaboration Go to article: Rewriting the pharma supply chain for a post-pandemic world Go to article: Developing an oral Covid-19 vaccine Go to article: The Solubility Company - Company Insight Go to article: The Solubility company Go to article: In Data Go to article: Deals analysis Go to article: The pharma industry key list Go to article: Global markets and indices Go to article: Macro-economic indicators Go to article: Macro-economic indicators (page 2)Go to article: Events Go to article: Next issue